US FDA Recalibrates Office Of Generic Drugs
As Part Of Wider Structural Changes To CDER
Executive Summary
As part of a wider overhaul of the FDA’s Center for Drug Evaluation and Research, the agency is reorganizing its Office of Generic Drugs, including adding a new Office of Safety and Clinical Evaluation within the OGD.
You may also be interested in...
Innovent Expands Internationally With Indonesia Deal
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
FDA Guides On Bioequivalence Studies And COVID-19
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Teva Takes On Amneal With Second US NuvaRing Rival
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: